Top 3 Growth Companies With High Insider Ownership On Euronext Paris
Reviewed by Simply Wall St
As global markets react to weak U.S. economic data, the French CAC 40 Index has seen a notable decline of 3.54%, reflecting broader concerns about growth and economic stability in Europe. In this environment, investors often look for resilient growth companies with high insider ownership, as these firms typically demonstrate strong alignment between management and shareholder interests. In this article, we will explore three standout growth companies listed on Euronext Paris that exhibit significant insider ownership, offering potential stability and long-term value amidst market volatility.
Top 10 Growth Companies With High Insider Ownership In France
Name | Insider Ownership | Earnings Growth |
Groupe OKwind Société anonyme (ENXTPA:ALOKW) | 24.8% | 36% |
VusionGroup (ENXTPA:VU) | 13.4% | 25.7% |
Adocia (ENXTPA:ADOC) | 11.9% | 63% |
Icape Holding (ENXTPA:ALICA) | 30.2% | 35.1% |
Arcure (ENXTPA:ALCUR) | 21.4% | 27.5% |
La Française de l'Energie (ENXTPA:FDE) | 19.9% | 31.9% |
S.M.A.I.O (ENXTPA:ALSMA) | 17.3% | 35.2% |
Munic (ENXTPA:ALMUN) | 29.4% | 149.2% |
OSE Immunotherapeutics (ENXTPA:OSE) | 25.6% | 5.9% |
MedinCell (ENXTPA:MEDCL) | 16.4% | 71.1% |
Let's dive into some prime choices out of the screener.
Lectra (ENXTPA:LSS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lectra SA provides industrial intelligence solutions for the fashion, automotive, and furniture markets across Northern Europe, Southern Europe, the Americas, and the Asia Pacific with a market cap of €954.56 million.
Operations: The company's revenue segments include €172.65 million from the Americas and €118.54 million from the Asia-Pacific region, with a segment adjustment of €209.13 million.
Insider Ownership: 19.6%
Lectra SA, a French growth company with high insider ownership, reported half-year sales of €262.29 million, up from €239.55 million a year ago, though net income declined to €12.51 million from €14.47 million. Revenue is forecasted to grow at 10.5% annually, outpacing the French market's 5.8%. Earnings are expected to increase significantly by 32.6% per year over the next three years and analysts project a potential stock price rise of 37.2%.
- Dive into the specifics of Lectra here with our thorough growth forecast report.
- Our valuation report unveils the possibility Lectra's shares may be trading at a discount.
MedinCell (ENXTPA:MEDCL)
Simply Wall St Growth Rating: ★★★★★☆
Overview: MedinCell S.A., with a market cap of €456.68 million, is a pharmaceutical company in France that develops long-acting injectables across various therapeutic areas.
Operations: MedinCell generates its revenue from the Pharmaceuticals segment, amounting to €11.95 million.
Insider Ownership: 16.4%
MedinCell, a French growth company with high insider ownership, is forecasted to achieve substantial revenue growth of 44.7% annually and become profitable within three years. Despite recent challenges, including a net loss of €25.04 million for the fiscal year ending March 2024 and mixed results from its Phase 3 trials for F14, the company's innovative BEPO® technology shows promise. MedinCell's stock trades at nearly 90% below its estimated fair value, indicating potential undervaluation.
- Click to explore a detailed breakdown of our findings in MedinCell's earnings growth report.
- Our comprehensive valuation report raises the possibility that MedinCell is priced higher than what may be justified by its financials.
VusionGroup (ENXTPA:VU)
Simply Wall St Growth Rating: ★★★★★★
Overview: VusionGroup S.A. offers digitalization solutions for commerce across Europe, Asia, and North America, with a market cap of €2.15 billion.
Operations: VusionGroup generates €801.96 million in revenue from installing and maintaining electronic shelf labels.
Insider Ownership: 13.4%
VusionGroup, a French growth company with high insider ownership, has recently partnered with Ace Hardware to implement its advanced digital shelf label technology across over 5,000 U.S. stores. This collaboration aims to enhance customer experience and operational efficiency. VusionGroup's revenue is forecasted to grow 21.3% annually, outpacing the French market average of 5.8%. Despite recent volatility in its share price, analysts project a significant earnings growth of 25.74% per year over the next three years.
- Click here to discover the nuances of VusionGroup with our detailed analytical future growth report.
- Our valuation report here indicates VusionGroup may be overvalued.
Seize The Opportunity
- Gain an insight into the universe of 23 Fast Growing Euronext Paris Companies With High Insider Ownership by clicking here.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About ENXTPA:MEDCL
MedinCell
A pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
High growth potential and fair value.